INLYTA

This brand name is authorized in Austria, Australia, Brazil, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States

Active ingredients

The drug INLYTA contains one active pharmaceutical ingredient (API):

1 Axitinib
UNII C9LVQ0YUXG - AXITINIB

Axitinib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2 and VEGFR-3. These receptors are implicated in pathologic angiogenesis, tumour growth, and metastatic progression of cancer. Axitinib has been shown to potently inhibit VEGF-mediated endothelial cell proliferation and survival.

Read about Axitinib

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
INLYTA Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
INLYTA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L01EK01 Axitinib L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
Discover more medicines within L01EK01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: AU Pharmaceutical Benefits Scheme Identifier(s): 10539Q, 10540R, 10556N, 10572K
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 522720020083617, 522720020083717
Country: CA Health Products and Food Branch Identifier(s): 02389630, 02389649
Country: EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria Identifier(s): H5250513
Country: EE Ravimiamet Identifier(s): 1593301, 1593312, 1593323, 1593334, 1593345, 1593356, 1623967, 1623978, 1623989, 1623990, 1624003, 1624014
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 12777002, 12777005
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 103854, 599010
Country: FR Base de données publique des médicaments Identifier(s): 61357910, 64922489, 67939209, 69083347
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 215059, 215062, 245079, 245082, 392402
Country: HK Department of Health Drug Office Identifier(s): 62088, 62089
Country: IE Health Products Regulatory Authority Identifier(s): 88116, 88117
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 7169, 7321
Country: JP 医薬品医療機器総合機構 Identifier(s): 4291027F1029, 4291027F2025
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1067711, 1067712, 1067713, 1067714, 1067715, 1067716, 1075260, 1075261, 1075262, 1075263, 1075264, 1075265
Country: NL Z-Index G-Standaard, PRK Identifier(s): 104442, 104450, 114650
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 15630, 15631
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100084494, 100208499, 100285070, 100285086
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W64813001, W64813002, W64813003, W64814001, W64814002, W64814003
Country: SG Health Sciences Authority Identifier(s): 14321P, 14322P
Country: TN Direction de la Pharmacie et du Médicament Identifier(s): 15833011H, 15833012H, 15833013H, 15833014H
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8681308099181, 8681308099198, 8681308099204, 8681308099211, 8681308099228, 8681308099235, 8681308099754, 8681308099761
Country: US FDA, National Drug Code Identifier(s): 0069-0145, 0069-0151, 63539-026, 63539-044

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.